Igc Pharma Inc IGC

$0.18 -0.01 (-4.61%)

Valuation

Market cap
21,529,000
Revenue TTM
$1,271,000
Net income TTM
$-7,121,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.18

Trading

Volume
509,400
Avg volume
569,428
Day's range
$0.17 – $0.19
Shares out
116,687,000
Stochastic %K
21%
Beta
0.55
Analysts
Moderate Buy
Price target
$4.50

Price

Company profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-...

Show more

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Industry
Biotechnology
Sector
Healthcare
Phone
301 983 0998
Website
https://igcpharma.com
Address
10224 Falls Road, Potomac, United States

Latest news

Stocktwits

RocketQueen Nov 14, 3:09 AM
$IGC Because IGC-AD1 has already demonstrated statistical significance on the exact same primary endpoint (Week 6 CMAI) in an interim look and expanded its final sample size to protect statistical power, the clinical odds lean favorably toward hitting the primary endpoint. -GAI
0 replies
RocketQueen Nov 14, 12:12 AM
$IGC again, there literally was another penny stock company yesterday (OGEN) that failed their phase II clinical trials, and it's already trading above IGC in the .20s after a dip down to .17. This really makes no sense at all for IGC to be trading so low in a double blind test. IGC is miles ahead of OGEN in just about every category.
0 replies
RocketQueen Nov 13, 10:24 PM
$IGC they need a positive PR soon....
0 replies
Deelam Nov 13, 6:57 PM
$IGC they are continually pushing off data lock and results. None of their PRs land anymore. Everyone is getting fed up.
0 replies
RocketQueen Nov 13, 4:31 PM
$IGC this is trading like they failed the trial. ı’ve never seen this in the lead up to results. For comparison, OGEN just failed and it is trading at the same price. I’m bullish but don’t understand. what gives?
0 replies
RocketQueen Nov 13, 3:23 PM
$IGC the offset here is due to a single sale last week. We should start to see creep up to data lock.
1 replies
RocketQueen Nov 13, 1:32 AM
$IGC grossly underpriced...
0 replies
SaySomethingNice Nov 12, 11:18 PM
$IGC 3 news tba for this company. 3 NEWS FOR INVESTORS TO DO DD. 3 NEWS TRIFECTA $$$$.. PHASE2 DATA RESULT AI PLATFORMS CEO, clearly, SAID LOOKING FOR BUYOUT $$$$ WITH PHASE 2 DATA RESULT. DEMENTIA, AI INFO, MEANS SIGNIFICANT INTEREST FOR PHARMACEUTICAL GIANTS TO DIGEST. That is why EXPERT price target $IGC at $6+ pps at minimum. That's a 1000%-3000% on the horizon ahead. Remember, BIOTECH PLAYS CAN GAP UP TO THE MOON INSTANTLY. Imo, here..
1 replies